Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/302% above fair value
$64.63−1.20 (-1.82%)
Close on Nov 20, 2026Market cap $15.77BP/E 19.4Yield –
Exelixis shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Exelixis's shares outstanding was 256M at Oct 2, 2026. For fiscal 2025 it was 282M, down 4.8% from the year before. Over ten years it grew 3.0% a year on average. The highest annual figure on record is 325M in fiscal 2022.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 282M | -4.8% |
| FY2024 | Jan 3, 2025 | 296M | -7.9% |
| FY2023 | Dec 29, 2023 | 321M | -1.0% |
| FY2022 | Dec 30, 2022 | 325M | +0.7% |
| FY2021 | Dec 31, 2021 | 322M | +1.4% |
| FY2020 | Jan 1, 2021 | 318M | +0.9% |
| FY2019 | Jan 3, 2020 | 315M | +0.7% |
| FY2018 | Dec 28, 2018 | 313M | +0.3% |
| FY2017 | Dec 29, 2017 | 312M | +24.5% |
| FY2016 | Dec 31, 2016 | 251M | +19.7% |
| FY2015 | Dec 31, 2015 | 209M | +7.7% |
| FY2014 | Dec 31, 2014 | 194M | +5.6% |
| FY2013 | Dec 31, 2013 | 184M | +14.9% |
| FY2012 | Dec 31, 2012 | 160M | +22.7% |
| FY2011 | Dec 31, 2011 | 130M | +20.2% |
| FY2010 | Dec 31, 2010 | 109M | +1.4% |
| FY2009 | Dec 31, 2009 | 107M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | 256M | -8.2% |
| Q2 FY2026 | Jul 3, 2026 | 260M | -8.7% |
| Q1 FY2026 | Apr 3, 2026 | 267M | -7.2% |
| Q4 FY2025 | Jan 2, 2026 | 276M | -5.9% |
| Q3 FY2025 | Oct 3, 2025 | 279M | -4.4% |
| Q2 FY2025 | Jul 4, 2025 | 284M | -3.3% |
| Q1 FY2025 | Apr 4, 2025 | 288M | -5.7% |
| Q4 FY2024 | Jan 3, 2025 | 294M | -6.2% |
| Q3 FY2024 | Sep 27, 2024 | 291M | -8.7% |
| Q2 FY2024 | Jun 28, 2024 | 294M | -10.2% |
| Q1 FY2024 | Mar 29, 2024 | 306M | -6.4% |
| Q4 FY2023 | Dec 29, 2023 | 313M | -3.7% |
| Q3 FY2023 | Sep 29, 2023 | 319M | -1.8% |
| Q2 FY2023 | Jun 30, 2023 | 327M | +0.7% |
| Q1 FY2023 | Mar 31, 2023 | 326M | +0.9% |
| Q4 FY2022 | Dec 30, 2022 | 325M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | 325M | +0.9% |
| Q2 FY2022 | Jul 1, 2022 | 325M | +0.6% |
| Q1 FY2022 | Apr 1, 2022 | 323M | +0.6% |
| Q4 FY2021 | Dec 31, 2021 | 323M | +1.1% |
| Q3 FY2021 | Oct 1, 2021 | 322M | +4.2% |
| Q2 FY2021 | Jul 2, 2021 | 323M | +1.5% |
| Q1 FY2021 | Apr 2, 2021 | 321M | +1.7% |
| Q4 FY2020 | Jan 1, 2021 | 320M | +1.5% |
| Q3 FY2020 | Oct 2, 2020 | 309M | -2.0% |
| Q2 FY2020 | Jul 3, 2020 | 318M | +1.0% |
| Q1 FY2020 | Apr 3, 2020 | 316M | +0.4% |
| Q4 FY2019 | Jan 3, 2020 | 315M | +1.1% |
| Q3 FY2019 | Sep 27, 2019 | 315M | +1.0% |
| Q2 FY2019 | Jun 28, 2019 | 315M | +0.9% |
| Q1 FY2019 | Mar 29, 2019 | 315M | +0.3% |
| Q4 FY2018 | Dec 28, 2018 | 312M | -0.6% |
| Q3 FY2018 | Sep 28, 2018 | 312M | -0.2% |
| Q2 FY2018 | Jun 29, 2018 | 312M | +0.3% |
| Q1 FY2018 | Mar 30, 2018 | 314M | +1.3% |
| Q4 FY2017 | Dec 29, 2017 | 313M | +8.8% |
| Q3 FY2017 | Sep 30, 2017 | 313M | – |
| Q2 FY2017 | Jun 30, 2017 | 311M | – |
| Q1 FY2017 | Mar 31, 2017 | 310M | – |
| Q4 FY2016 | Dec 31, 2016 | 288M | – |
See a number that looks wrong?